石墨烯基聚苯胺载AgAu双金属复合催化剂及其制备和应用
By constructing a graphene-based polyaniline-supported AgAu bimetallic composite catalyst, the detection problem of dopamine and ascorbic acid in blood or urine was solved, achieving highly sensitive and selective detection of dopamine, thus overcoming the insufficient selectivity and sensitivity of existing dopamine detection technologies.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- NINGDE NORMAL UNIV
- Filing Date
- 2026-03-20
- Publication Date
- 2026-07-17
AI Technical Summary
Existing technologies struggle to detect dopamine (DA) with high sensitivity and selectivity in real biological samples such as blood or urine. This is because dopamine, ascorbic acid (AA), and uric acid (UA) have similar oxidation potentials on conventional electrodes, leading to signal overlap and affecting the selectivity and sensitivity of the sensor.
A graphene-based polyaniline-supported AgAu bimetallic composite catalyst was constructed by forming an open-pore composite spherical structure under Fe3+ coordination, loading AgAu bimetallic nanoparticles, and optimizing the electronic structure to improve catalytic activity and selectivity.
It significantly improves the oxidation peak current of dopamine, reduces the interference of uric acid and ascorbic acid, and achieves highly sensitive detection of dopamine with a detection limit as low as 0.001 μM, which meets the requirements for accurate determination of dopamine content in human body fluids.
Smart Images
Figure CN121869459B_ABST